期刊文献+

多发性骨髓瘤的免疫表型特征及其意义 被引量:5

Immunophenotype characteristics in multiple myeloma cells and its significance
下载PDF
导出
摘要 目的探讨多发性骨髓瘤(MM)的细胞免疫表型特征及意义。方法应用多参数流式细胞术(MPFCM)测定多发性骨髓瘤30例和反应性免疫球蛋白增高症患者15例(对照组)骨髓细胞的免疫表型。结果 MM组CD138和CD38阳性率均为100%,CD56阳性率86.67%,CD117阳性率33.33%,CD19阳性率仅3.33%;对照组CD38、CD138阳性率均为100%,CD19阳性率93.33%,CD56阳性率6.67%,CD117不表达。MM组浆细胞比例及CD138、CD56、CD117表达率均高于对照组(P<0.01),CD19表达率低于对照组(P<0.01)。结论应用MP-FCM同时检测细胞表面CD38、CD138、CD19、CD56、CD117等抗原表达情况,可方便区分骨髓瘤细胞与良性浆细胞,是多发性骨髓瘤的重要诊断依据。 Objective To investigate the immunophenotype characteristics in multiple myeloma(MM)cells and its significance.Methods Four color multiparameter flow cytometry(MP-FCM)was used to test immunophenotype of 30 MM patients and 15 patients with reactive gammopathy.Results The antigen positive expression rale in myeloma cells was as follows: CD138:100%,CD38;100%,CD56:86.67%,GDI 17:33.33%,CD19:3.33%.The results of patients with reactive gammopathy show that CD38 and CD138 were 100%positive,and CD19 was 93.33%positive,CD56 was 6.67%positive, while GD117 was negative.The expression of GD138,GD56 and GD117 in MM group were higher than the control group (P<0.01),expression of CD19 was lower than the control group(P<0.01)Conclusion MP-FCM is an important diagnostic method for MM and detect the GD38,CD138,CD19,CD56 and GD117 can he helpful for distinguishing myeloma cells from plasma cells.
出处 《疑难病杂志》 CAS 2012年第2期115-117,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 多发性骨髓瘤 免疫表型 流式细胞术 Multiple myeloma Immunophenotype Flow cytometry
  • 相关文献

参考文献10

  • 1Raja KR, Kovarova L, Hajek R; et al. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders[ J]. Sr J Haematol, 2010, 149(3): 334-351.
  • 2Paiva B, Almeida J, Perez-Andres M, et al. Utility of flow cytometry immunophenotyping in mu!tiple myeloma and other clonal plasma cell-re- lated disorders [ J]. Cytometty B Clin Cytom, 2010,78 (4) : 239-252.
  • 3Bashey A, Cantwell MJ, Kipps TJ ,et al Adenovirus transduction to effect CD40 signaling improves the immune stimulatory activity of myeloma cells [ J ]. Br J Haemato1,2002 , 108 ( 2 ) :506-513.
  • 4Gonzalez M, San Miguel JF, Gascon A, et al. Increas expression of nature- killer:associated and activtionlantigens in multiple myeloma[ J]. Am J Heamatol, 1992,39 (2) :84,89.
  • 5Blade J, de Larrea CFiRosino1 L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach [ J ]. J Clin Oncol, 2011,29 (28) : 3805-3812.
  • 6李娟,罗绍凯,张国材,洪文德,童秀珍.CD_(117)在多发性骨髓瘤细胞中的表达及其意义[J].癌症,2004,23(8):951-954. 被引量:7
  • 7孙莹,方美云,刘越坚.多发性骨髓瘤免疫表型特征及其意义[J].中国实验血液学杂志,2010,18(2):381-384. 被引量:20
  • 8Rawstron AC,Orfao A, Beksac M, et al. Report of the European MyeIo- ma Network on multiparametric flow cytometry in multiple myeloma and related disorders[ J]. Haematologica, 2008, 93 (3) : 431-438,.
  • 9Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma ceils at diagnosis provides more prognostic information than morphological assessment in myeloma patients ~J]. Haematologica,2009, 94(11 ) : 1599-1602.
  • 10徐秀芹,刘春霞.多发性骨髓瘤40例血清免疫学特征[J].河北医药,2008,30(10):1523-1524. 被引量:3

二级参考文献26

  • 1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学(输血及血液学分册),1993,16(1):35-37. 被引量:11
  • 2李守静,李宏然,赵相印,李清朗.多发性骨髓瘤诊断的探讨(附2547例分析)[J].中华肿瘤杂志,1995,17(1):43-46. 被引量:151
  • 3庄俊玲,汪玄,武永吉.CD138/Syndecan-1在多发性骨髓瘤免疫表型中的意义[J].中国实验血液学杂志,2005,13(6):1023-1027. 被引量:10
  • 4Lin TL,ShihLY,Dunn P,et al.Lmmunogtobulin D multiple myeloma.Chang Gung Med J,2000,23:451-457.
  • 5Kara IO, Sahin B, Paydas S, et al. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Saudi Med J, 2004; 25( 11 ) : 1587 - 1592.
  • 6Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number o4 reagents required to evaluate hematolymphoid neoplasia: results of an international consensus meeting. Cytometry, 2001 ;46 ( 1 ) :23 27.
  • 7Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 2004, 121 (4): 482-488.
  • 8Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1 ^+ malignant plasma cells. J lmmunol Methods, 1997 ;205 ( 1 ) :73 - 79.
  • 9Matsui W, Huff CA, Wang QJ, et al. Characterization of clonogenic multiple myeloma cells. Blood, 2004 ; 103 (6) : 2332 - 2336.
  • 10Aref S, Goda T, El-Sherbiny M. Syndecan-I in multiple myeloma: relationship to conventional prognostic factors. Hematology, 2003 ; 8(4) :221 -228.

共引文献23

同被引文献26

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部